Granules Eyes First-to-File Status for Ruxolitinib with 180 Days Exclusivity in US
Granules Eyes First-to-File Status for Ruxolitinib with 180 Days Exclusivity in US Granules India, a leading pharmaceutical company, has filed an Abbreviated New Drug Application (ANDA) with the United States Food and Drug Administration (FDA) for generic [...]
